[go: up one dir, main page]

WO2005078139A3 - Diagnostic et traitement de cancers a l'aide de microarn present dans ou au voisinage de caracteristiques chromosomiennes liees aux cancers - Google Patents

Diagnostic et traitement de cancers a l'aide de microarn present dans ou au voisinage de caracteristiques chromosomiennes liees aux cancers Download PDF

Info

Publication number
WO2005078139A3
WO2005078139A3 PCT/US2005/004865 US2005004865W WO2005078139A3 WO 2005078139 A3 WO2005078139 A3 WO 2005078139A3 US 2005004865 W US2005004865 W US 2005004865W WO 2005078139 A3 WO2005078139 A3 WO 2005078139A3
Authority
WO
WIPO (PCT)
Prior art keywords
chromosomal
cancer
cancers
gene expression
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/004865
Other languages
English (en)
Other versions
WO2005078139A2 (fr
Inventor
Carlo M Croce
Chang-Gong Liu
George A Calin
Cinzia Sevignani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002554818A priority Critical patent/CA2554818A1/fr
Priority to EP05723130A priority patent/EP1713938A2/fr
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Priority to US11/194,055 priority patent/US7723030B2/en
Publication of WO2005078139A2 publication Critical patent/WO2005078139A2/fr
Publication of WO2005078139A3 publication Critical patent/WO2005078139A3/fr
Anticipated expiration legal-status Critical
Priority to US12/751,463 priority patent/US20100203544A1/en
Priority to US12/767,279 priority patent/US20100234241A1/en
Priority to US13/972,759 priority patent/US8778676B2/en
Priority to US14/281,756 priority patent/US9150859B2/en
Priority to US14/846,193 priority patent/US9506065B2/en
Priority to US15/237,396 priority patent/US20170175123A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Les gènes de microARN sont nettement associés à des caractéristiques chromosomiennes impliquées dans l'étiologie de différents cancers. Les perturbations de la structure du génome ou de la structure du chromosome, d'une cellule, dues auxdites caractéristiques chromosomiennes, peuvent affecter l'expression des gènes de microARN situés à proximité immédiate de ces caractéristiques. C'est pourquoi on peut utiliser l'évaluation de l'expression des gènes de microARN pour indiquer la présence d'une lésion chromosomienne cancérigène. Comme une variation du niveau de l'expression des gènes de microARN due à des caractéristiques chromosomiennes liées au cancer peut également contribuer à la cancérogenèse, on peut traiter un cancer donné en ramenant à la normale ledit niveau d'expression.
PCT/US2005/004865 2004-02-09 2005-02-09 Diagnostic et traitement de cancers a l'aide de microarn present dans ou au voisinage de caracteristiques chromosomiennes liees aux cancers Ceased WO2005078139A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002554818A CA2554818A1 (fr) 2004-02-09 2005-02-09 Diagnostic et traitement de cancers a l'aide de microarn present dans ou au voisinage de caracteristiques chromosomiennes liees aux cancers
EP05723130A EP1713938A2 (fr) 2004-02-09 2005-02-09 Diagnostic et traitement de cancers a l'aide de microarn present dans ou au voisinage de caracteristiques chromosomiennes liees aux cancers
US11/194,055 US7723030B2 (en) 2004-02-09 2005-07-29 Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features
US12/751,463 US20100203544A1 (en) 2004-02-09 2010-03-31 DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER ASSOCIATED CHROMOSOMAL FEATURES
US12/767,279 US20100234241A1 (en) 2004-02-09 2010-04-26 DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
US13/972,759 US8778676B2 (en) 2004-02-09 2013-08-21 Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
US14/281,756 US9150859B2 (en) 2004-02-09 2014-05-19 Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
US14/846,193 US9506065B2 (en) 2004-02-09 2015-09-04 Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
US15/237,396 US20170175123A1 (en) 2004-02-09 2016-08-15 Diagnosis And Treatment Of Cancers With MicroRNA Located In Or Near Cancer-Associated Chromosomal Features

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US54311904P 2004-02-09 2004-02-09
US54296304P 2004-02-09 2004-02-09
US54292904P 2004-02-09 2004-02-09
US54294004P 2004-02-09 2004-02-09
US60/542,963 2004-02-09
US60/542,929 2004-02-09
US60/542,940 2004-02-09
US60/543,119 2004-02-09
US58095904P 2004-06-18 2004-06-18
US58079704P 2004-06-18 2004-06-18
US60/580,797 2004-06-18
US60/580,959 2004-06-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/194,055 Continuation-In-Part US7723030B2 (en) 2004-02-09 2005-07-29 Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features

Publications (2)

Publication Number Publication Date
WO2005078139A2 WO2005078139A2 (fr) 2005-08-25
WO2005078139A3 true WO2005078139A3 (fr) 2006-03-23

Family

ID=34865553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/004865 Ceased WO2005078139A2 (fr) 2004-02-09 2005-02-09 Diagnostic et traitement de cancers a l'aide de microarn present dans ou au voisinage de caracteristiques chromosomiennes liees aux cancers

Country Status (4)

Country Link
US (7) US7723030B2 (fr)
EP (2) EP2295604B1 (fr)
CA (1) CA2554818A1 (fr)
WO (1) WO2005078139A2 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943318B2 (en) 2006-01-05 2011-05-17 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
US7985584B2 (en) 2006-03-20 2011-07-26 The Ohio State University Research Foundation MicroRNA fingerprints during human megakaryocytopoiesis
US8034560B2 (en) 2007-01-31 2011-10-11 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML)
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
US8084199B2 (en) 2006-07-13 2011-12-27 The Ohio State University Research Foundation Method of diagnosing poor survival prognosis colon cancer using microRNA-21
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
US8367632B2 (en) 2007-07-31 2013-02-05 Ohio State University Research Foundation Methods for reverting methylation by targeting methyltransferases
US8389210B2 (en) 2006-01-05 2013-03-05 The Ohio State University Research Foundation MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
US8465918B2 (en) 2007-08-03 2013-06-18 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
US8466119B2 (en) 2007-08-22 2013-06-18 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of EPHA7 and ERK phosphorylation in human acute leukemias
US8465917B2 (en) 2007-06-08 2013-06-18 The Ohio State University Research Foundation Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells
US8481505B2 (en) 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
US8658370B2 (en) 2005-08-01 2014-02-25 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
US8911998B2 (en) 2007-10-26 2014-12-16 The Ohio State University Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof
US8946177B2 (en) 2004-11-12 2015-02-03 Mima Therapeutics, Inc Methods and compositions involving miRNA and miRNA inhibitor molecules
US9125923B2 (en) 2008-06-11 2015-09-08 The Ohio State University Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
US9771585B2 (en) 2015-06-05 2017-09-26 MiRagen Therapeutics, Inc. miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)
US9803202B2 (en) 2012-06-21 2017-10-31 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
US10280422B2 (en) 2015-01-20 2019-05-07 MiRagen Therapeutics, Inc. MiR-92 inhibitors and uses thereof

Families Citing this family (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906326B2 (en) * 2003-05-07 2011-03-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides associated with alzheimer's disease and uses thereof
GB2424887B (en) * 2003-11-26 2008-05-21 Univ Massachusetts Sequence-specific inhibition of small RNA function
CA2554818A1 (fr) 2004-02-09 2005-08-25 Thomas Jefferson University Diagnostic et traitement de cancers a l'aide de microarn present dans ou au voisinage de caracteristiques chromosomiennes liees aux cancers
CN101056991A (zh) * 2004-04-20 2007-10-17 基因耐克生物医学制品有限公司 检测ncRNA的方法
US8563252B2 (en) 2004-05-14 2013-10-22 Rosetta Genomics Ltd. Methods for distinguishing between lung squamous carcinoma and other non small cell lung cancers
AU2005250432B2 (en) * 2004-05-28 2011-09-15 Asuragen, Inc. Methods and compositions involving microRNA
AU2011253959B2 (en) * 2004-05-28 2014-05-15 Asuragen, Inc. Methods and compositions involving MicroRNA
FR2877350B1 (fr) * 2004-11-03 2010-08-27 Centre Nat Rech Scient IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE
US20070166724A1 (en) * 2005-02-07 2007-07-19 Itzhak Bentwich Micrornas and related nucleic acids
CA2603881A1 (fr) 2005-04-04 2006-10-12 The Board Of Regents Of The University Of Texas System Microarn regulant des cellules musculaires
CA2607256A1 (fr) 2005-05-02 2006-11-09 Cold Spring Harbor Laboratory Compositions et procedes destines au diagnostic et au traitement du cancer
US20070054287A1 (en) * 2005-05-31 2007-03-08 Applera Corporation Method for identifying medically important cell populations using micro rna as tissue specific biomarkers
JP2008541737A (ja) * 2005-06-03 2008-11-27 サウザーン アデレード ヘルス サービス−ファインダーズ メディカル センター マイクロｒｎａ発現の変化した細胞を標的とすること
GB0517466D0 (en) * 2005-08-26 2005-10-05 Immunodiagnostic Systems Plc Diagnostic assay and therapeutic treatment
US20080234213A1 (en) * 2005-09-02 2008-09-25 Matthias Wabl Oncogenic regulatory RNAs for diagnostics and therapeutics
EP1940456A4 (fr) * 2005-10-05 2009-10-21 Univ Ohio State Res Found Gene wwox, vecteurs renfermant celui-ci et utilisations de ceux-ci dans le traitement de cancer
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
AU2016203848B2 (en) * 2006-01-05 2017-12-14 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
AU2012238336B8 (en) * 2006-01-05 2014-08-07 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
AU2013206405B2 (en) * 2006-01-05 2016-02-04 The Ohio State University Research Foundation MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
AU2014203454B2 (en) * 2006-01-05 2016-03-17 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
EP2505668A3 (fr) * 2006-01-05 2013-01-09 The Ohio State University Research Foundation Procédés à base de micro ARN pour le diagnostic d'un cancer du colon, du poumon, et du pancreas
FI121236B (fi) * 2006-01-18 2010-08-31 Licentia Oy Menetelmä asbestialtistukseen liittyvien keuhkosyöpien tunnistamiseksi
GB0603251D0 (en) 2006-02-17 2006-03-29 Isis Innovation DNA conformation
US20100286232A1 (en) * 2006-03-02 2010-11-11 The Ohio State University Microrna expression profile associated with pancreatic cancer
ES2569558T3 (es) 2006-04-03 2016-05-11 Roche Innovation Center Copenhagen A/S Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi
CA3042781C (fr) 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Composition pharmaceutique comprenant des oligonucleotides antisens anti-microarn
US8207325B2 (en) * 2006-04-03 2012-06-26 Univ. of Copenhagen MicroRNA biomarkers for human breast and lung cancer
US8039234B1 (en) * 2006-05-22 2011-10-18 Applied Biosystems, Llc Methods, panels of identification markers, and kits for identifying forensic samples
WO2007150071A1 (fr) * 2006-06-23 2007-12-27 Myriad Genetics, Inc. Amplifications et délétions de gènes
WO2008002672A2 (fr) 2006-06-28 2008-01-03 The Cleveland Clinic Foundation Cibles utilisées pour le diagnostic, le pronostic et la thérapie du cancer
AU2007281261B2 (en) 2006-08-01 2013-03-21 Board Of Regents Of The University Of Texas System Identification of a micro-RNA that activates expression of beta-myosin heavy chain
WO2008024343A2 (fr) * 2006-08-21 2008-02-28 The University Of North Carolina At Chapel Hill Puces à micro-arn et leurs procédés d'utilisation
CA2664383C (fr) * 2006-09-19 2017-08-22 Asuragen, Inc. Micro arn exprimes par differenciation dans les maladies du pancreas, et leur utilisation
EP2086590A4 (fr) 2006-10-24 2011-04-06 Univ Leland Stanford Junior Modulation du seuil de signalisation des lymphocytes t et de la sensibilité des lymphocytes t aux antigènes
US8343719B2 (en) * 2006-10-30 2013-01-01 Research Foundation Of State University Of New York Microrna as biomarker in cancer
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
JP2010510769A (ja) * 2006-11-28 2010-04-08 キャピタルバイオ コーポレーション 食道癌の診断ならびに患者の生存の予後および改善のための方法および組成物
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
WO2008073915A2 (fr) * 2006-12-08 2008-06-19 Asuragen, Inc. Microarn exprimés de manière différentielle en cas de leucémie et leurs utilisations
AU2007333106A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. miR-20 regulated genes and pathways as targets for therapeutic intervention
WO2008079303A2 (fr) 2006-12-20 2008-07-03 The Brigham And Women's Hospital, Inc. Détection de rejet d'organe
US20100086928A1 (en) * 2006-12-20 2010-04-08 The Brigham And Women's Hospital, Inc. Detection of organ rejection
CA2671270A1 (fr) * 2006-12-29 2008-07-17 Asuragen, Inc. Genes et voies regules par mir-16 utiles comme cibles pour intervention therapeutique
EP2111408A4 (fr) * 2007-01-17 2010-02-03 Univ Johns Hopkins Compositions et procédés comprenant des microarn pour traiter une néoplasie
WO2008092099A2 (fr) * 2007-01-26 2008-07-31 Rosetta Genomics, Ltd. Compositions et procédés de traitement de malignités hématopoïétiques
WO2008104974A2 (fr) * 2007-02-27 2008-09-04 Rosetta Genomics Ltd. Composition et méthodes de modulation de la prolifération et de la mort cellulaire
US9006206B2 (en) 2007-02-27 2015-04-14 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
EP2126115A2 (fr) 2007-03-01 2009-12-02 Rosetta Genomics Ltd Diagnostic et pronostic de divers types de cancers
EP2126116A2 (fr) * 2007-03-01 2009-12-02 Rosetta Genomics Ltd Procédés pour distinguer un carcinome squameux du poumon d'autres cancers du poumon à non-petites cellules
WO2008115387A2 (fr) * 2007-03-15 2008-09-25 University Hospitals Of Cleveland Criblage, diagnostic, traitement et pronostic d'états pathophysiologiques par régulation d'arn
CN101688240A (zh) * 2007-04-10 2010-03-31 国立台湾大学 通过微rna预测癌症患者的治疗后存活预期
US20090105174A1 (en) * 2007-04-20 2009-04-23 Amgen Inc. Nucleic acids hybridizable to micro rna and precursors thereof
JP5592251B2 (ja) * 2007-04-30 2014-09-17 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 膵臓癌を正常な膵臓機能および／または慢性膵炎と識別する方法
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20100167948A1 (en) * 2007-05-22 2010-07-01 The Brigham And Women's Hospital, Inc. MicroRNA Expression Profiling of Cerebrospinal Fluid
CN101801419A (zh) * 2007-06-08 2010-08-11 米尔纳疗法公司 作为治疗干预的靶标的miR-34调控的基因和路径
AU2013224690B2 (en) * 2007-06-15 2015-07-09 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting drosha-mediated microRNA processing
US20130190379A1 (en) * 2007-07-06 2013-07-25 Edwin Pieter Johan Cuppen Small rna molecules, precursors thereof, means and methods for detecting them, and uses thereof in typing samples
WO2009012263A2 (fr) * 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Micro-arn à spécificité cellulaire et compositions et utilisations de ces micro-arn
JP5654347B2 (ja) 2007-07-31 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ミオシンの発現及び筋線維の同一性を制御するマイクロｒｎａ
ES2621161T3 (es) 2007-07-31 2017-07-03 The Board Of Regents Of The University Of Texas System Familia de micro-ARN que modula la fibrosis y usos de la misma
EP2188395A4 (fr) * 2007-08-17 2010-10-13 Catalyst Assets Llc Utilisation de micro-arn associés au cancer de la vessie humaine pour le diagnostic et de pronostic
AU2014202073B2 (en) * 2007-09-06 2015-06-25 The Ohio State University Research Foundation MicroRNA signatures in human ovarian cancer
EP2183393B1 (fr) * 2007-09-06 2014-06-11 The Ohio State University Research Foundation Signatures de microarn dans le cancer ovarien humain
EP2198050A1 (fr) * 2007-09-14 2010-06-23 Asuragen, INC. Microarn exprimés de manière différentielle dans le cancer du col de l'utérus et leurs utilisations
JPWO2009044899A1 (ja) * 2007-10-03 2011-02-17 協和発酵キリン株式会社 細胞の増殖を制御する核酸
CA2701547C (fr) 2007-10-04 2020-03-10 Santaris Pharma A/S Oligonucleotiques qui ciblent et inhibent les micro arn
US20100285471A1 (en) * 2007-10-11 2010-11-11 The Ohio State University Research Foundation Methods and Compositions for the Diagnosis and Treatment of Esphageal Adenocarcinomas
US20090186015A1 (en) * 2007-10-18 2009-07-23 Latham Gary J Micrornas differentially expressed in lung diseases and uses thereof
WO2009058907A2 (fr) 2007-10-29 2009-05-07 Isis Pharmaceuticals, Inc. Ciblage de microarn pour le traitement du cancer du foie
JP2011501949A (ja) * 2007-10-31 2011-01-20 ロゼッタ ゲノミックス エルティーディー． 特定の癌の診断及び予後診断
NZ585209A (en) 2007-11-09 2012-08-31 Univ Texas Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
WO2009070653A1 (fr) * 2007-11-30 2009-06-04 The Ohio State University Research Foundation Profilage et criblage d'expression de micro-arn dans du sang périphérique dans un cancer du poumon
WO2009070805A2 (fr) 2007-12-01 2009-06-04 Asuragen, Inc. Gènes régulés par le mir-124 et cheminements servant de cibles pour une intervention thérapeutique
US8476420B2 (en) * 2007-12-05 2013-07-02 The Wistar Institute Of Anatomy And Biology Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells
JP5116026B2 (ja) 2008-01-23 2013-01-09 富士フイルム株式会社 癌の検出方法および癌抑制剤
EP2238267A2 (fr) * 2008-01-24 2010-10-13 Université de Lausanne Procédé de prédiction et de diagnostic d'une tumeur cérébrale
WO2009105759A2 (fr) * 2008-02-21 2009-08-27 The Board Of Regents Of The University Of Texas System Micro-arn qui modulent la prolifération et la différentiation des muscles lisses et leurs utilisations
WO2009108856A2 (fr) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation Signatures de microarn associées à la leucémie lymphoïde chronique humaine (llc) et leurs utilisations
EP2250496A4 (fr) * 2008-02-28 2011-08-31 Univ Ohio State Res Found Signatures en micro-arn associées à la cytogénétique et au pronostic dans la leucémie myéloïde aiguë (aml) et leurs utilisations
EP2260109A4 (fr) * 2008-02-28 2011-06-08 Univ Ohio State Res Found Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate
JP2011515078A (ja) * 2008-03-01 2011-05-19 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ＳＰＡＲＣ特異的ｍｉＲＮＡを使用する、治療、診断、及び拮抗物質発見方法
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
ES2325726B1 (es) * 2008-03-13 2010-06-17 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Uso del microrna-203 y de sistemas de expresion del mismo para fabricar medicamentos contra el cancer.
US8202848B2 (en) 2008-03-17 2012-06-19 Board Of Regents, The University Of Texas System Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
WO2009126726A1 (fr) * 2008-04-08 2009-10-15 Asuragen, Inc Procédés et compositions pour diagnostiquer et moduler le papillomavirus humain (hpv)
EP2112235A1 (fr) * 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions et procédés pour le profilage de l'expression de microARN du carcinome du nasopharynx
WO2009137660A2 (fr) * 2008-05-07 2009-11-12 Abraxis Bioscience, Llc Amélioration de pharmacothérapie par précurseurs arn
EP2990487A1 (fr) 2008-05-08 2016-03-02 Asuragen, INC. Compositions et procédés relatifs à la modulation de miarn de néovascularisation ou angiogenèse
EP2123258A1 (fr) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes pour l'administration de médicaments
WO2009143603A1 (fr) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systèmes et procédés de discrimination basée sur l’expression d’états pathologiques cliniques distincts dans le cancer de la prostate
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
WO2009147658A2 (fr) * 2008-06-02 2009-12-10 New York University Compositions et procédés pour le diagnostic, le pronostic et le traitement d'un mésothéliome
WO2009149318A2 (fr) 2008-06-05 2009-12-10 Research Foundation Of State University Of New York Arnmi en tant que cibles thérapeutiques dans le cancer
WO2009148631A1 (fr) * 2008-06-06 2009-12-10 The Board Of Trustees Of The Leland Stanford Junior University Rôle d'un arnmi dans une leucémie à lymphocytes t
WO2009153774A2 (fr) * 2008-06-17 2009-12-23 Rosetta Genomics Ltd. Compositions et procédés pour le pronostic du cancer des ovaires
US20100234445A1 (en) * 2008-07-01 2010-09-16 Weng Onn Lui Patterns of known and novel small RNAS in human cervical cancer
US20100003674A1 (en) * 2008-07-03 2010-01-07 Cope Frederick O Adult stem cells, molecular signatures, and applications in the evaluation, diagnosis, and therapy of mammalian conditions
KR101043433B1 (ko) * 2008-07-18 2011-06-22 국립암센터 마이크로ｒｎａ분자를 포함하는 항암 조성물
US20100092961A1 (en) 2008-07-25 2010-04-15 The Cleveland Clinic Foundation Methods and compositions for detection of Cowden Syndrome (CS) and CS-like syndrome
WO2010014975A2 (fr) * 2008-08-01 2010-02-04 Academia Sinica Utilisation de signatures en micro-arn pour évaluer des niveaux de risque de neuroblastome
WO2010012667A1 (fr) 2008-08-01 2010-02-04 Santaris Pharma A/S Modulation à médiation par micro-arn de facteurs stimulateurs de colonies
US20110280861A1 (en) * 2008-08-08 2011-11-17 Massachusetts Institute Of Technology Method for mir-125a in promoting hematopoietic stem cell self renewal and expansion
WO2010018563A2 (fr) * 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions et procédés de pronostic d'un lymphome
EP2323677A4 (fr) * 2008-08-12 2013-01-09 Univ Ohio State Res Found Compositions à base de micro-arn et procédés de diagnostic, de pronostic et de traitement d un myélome multiple
WO2010034006A2 (fr) * 2008-09-22 2010-03-25 University Of Southern California Micro-arn-101 suppresseur de tumeur putatif modulant l'epigenome cancereux par repression de la proteine ezh2 du groupe polycomb
US20110301221A1 (en) * 2008-10-10 2011-12-08 Swedish Health Services Diagnosis, prognosis and treatment of glioblastoma multiforme
US9068974B2 (en) 2008-11-08 2015-06-30 The Wistar Institute Of Anatomy And Biology Biomarkers in peripheral blood mononuclear cells for diagnosing or detecting lung cancers
US9074206B2 (en) 2008-11-13 2015-07-07 Fudan University Compositions and methods for micro-RNA expression profiling of colorectal cancer
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
EP3467123A3 (fr) * 2008-11-17 2019-07-31 Veracyte, Inc. Procédés et compositions de profilage moléculaire pour le diagnostic de maladies
US20150197810A1 (en) * 2008-12-05 2015-07-16 Yeda Research And Development Co. Ltd. DOWNREGULATION OF miR-218 MAY BE USED AS A BIOMARKER FOR HUMAN ALS
US8206910B2 (en) 2008-12-08 2012-06-26 The Cleveland Clinic Foundation Targets for use in diagnosis, prognosis and therapy of breast cancer
US20110251086A1 (en) * 2008-12-10 2011-10-13 Joke Vandesompele Neuroblastoma prognostic multigene expression signature
US20120015049A1 (en) * 2009-01-14 2012-01-19 Lin Zhang Microrna biomarker in cancer
US20100240049A1 (en) 2009-01-16 2010-09-23 Cepheid Methods of Detecting Cervical Cancer
EP2379720B1 (fr) 2009-01-20 2016-08-17 Alona Zilberberg Thérapie anticancéreuse ciblée entraînée par le promoteur de mir-21
KR20110128838A (ko) 2009-02-04 2011-11-30 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 심장 질환 치료에서 ｍｉｒ－208 및 ｍｉｒ－499의 이중 표적화
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
IT1398768B1 (it) * 2009-03-24 2013-03-18 Zollo Uso di microrna-199b-5p in campo medico e diagnostico.
WO2010122538A1 (fr) 2009-04-24 2010-10-28 Santaris Pharma A/S Compositions pharmaceutiques pour le traitement de patients souffrant du vhc ne réagissant pas aux interférons
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
JP5995721B2 (ja) * 2009-08-28 2016-09-21 アスラジェン， インコーポレイテッド 肺疾患のｍｉＲＮＡバイオマーカー
US9157080B2 (en) 2009-09-09 2015-10-13 New York University Compositions and methods for treatment, diagnosis and prognosis of mesothelioma
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
EP2486929B1 (fr) * 2009-10-01 2017-03-15 National Cancer Center Agent thérapeutique anti-tumoral
US8771937B2 (en) * 2009-10-13 2014-07-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for diagnosing and treating a pathology associated with a synonymous mutation occuring within a gene of interest
JP5960060B2 (ja) 2009-11-23 2016-08-02 ジ・オハイオ・ステート・ユニバーシティ 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法
WO2011067346A1 (fr) * 2009-12-04 2011-06-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Procédé pour déterminer l'efficacité d'un traitement du cancer
EP2510122B1 (fr) * 2009-12-08 2017-04-12 Université Joseph Fourier Utilisation de miarns comme biomarqueurs dans le diagnostic de gliomes
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US8673875B2 (en) 2009-12-10 2014-03-18 Kaohsiung Medical University Method for treating atherosclerosis
US8354520B2 (en) * 2009-12-10 2013-01-15 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug
EP2341145A1 (fr) * 2009-12-30 2011-07-06 febit holding GmbH Empreinte ARNm dans le diagnostic de maladies
WO2011088309A1 (fr) 2010-01-14 2011-07-21 Regulus Therapeutics Inc. Compositions de microarn et procédés
US20130130927A1 (en) * 2010-03-11 2013-05-23 Helen Heneghan Detection and quantification of micrornas in the circulation and the use of circulating micrornas as biomarkers for cancer
JP5931050B2 (ja) * 2010-03-26 2016-06-08 ジ・オハイオ・ステート・ユニバーシティ ｍｉＲ−１５５によるミスマッチ修復およびゲノム安定性の調節に関連する材料および方法
US9145556B2 (en) 2010-04-13 2015-09-29 Life Technologies Corporation Compositions and methods for inhibition of nucleic acids function
CA2800557A1 (fr) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methodes et dispositifs permettant de predire l'efficacite d'un traitement
CN103038635B (zh) 2010-05-11 2016-12-28 威拉赛特公司 用于诊断病状的方法和组合物
CN103080334B (zh) * 2010-06-04 2016-05-04 复旦大学 用于诊断早期结直肠癌及高级腺瘤的微rna生物标记及方法
WO2012005572A1 (fr) 2010-07-06 2012-01-12 Interna Technologies Bv Miarn et ses utilisations diagnostiques et thérapeutiques pour des maladies ou des états associés au mélanome, ou pour des maladies ou des états associés à la voie braf activée
WO2012012716A2 (fr) 2010-07-23 2012-01-26 Regulus Therapeutics, Inc. Ciblage de microarn pour le traitement de la fibrose
WO2012017430A2 (fr) 2010-08-01 2012-02-09 Tel Hashomer Medical Research Infrastructure And Services Ltd. Profils de micro-arn destinés au diagnostic, au pronostic et au traitement d'un mélanome
US8933051B2 (en) * 2010-09-30 2015-01-13 University Of Zurich Treatment of B-cell lymphoma with microRNA
SG180031A1 (en) * 2010-10-15 2012-05-30 Agency Science Tech & Res Combination treatment of cancer
JP5931897B2 (ja) 2010-11-12 2016-06-08 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法
WO2012068147A1 (fr) 2010-11-15 2012-05-24 The Ohio State University Research Foundation Systèmes mucoadhésifs à libération contrôlée
WO2012068288A2 (fr) * 2010-11-16 2012-05-24 The Brigham And Women's Hospital, Inc. Diagnostic et surveillance de tumeurs malignes du snc à l'aide de microarn
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
WO2012083005A2 (fr) 2010-12-15 2012-06-21 Miragen Therapeutics Inhibiteurs de microarn comprenant des nucléotides bloqués
WO2012087242A1 (fr) * 2010-12-20 2012-06-28 Agency For Science, Technology And Research Ciblage de cellules souches de gliome par une inhibition fonctionnelle spécifique de l'oncogène mir-138 pro-survie
US8455518B2 (en) * 2010-12-28 2013-06-04 Avon Products, Inc. Method of treating skin with microRNA modulators
WO2012089753A2 (fr) * 2010-12-30 2012-07-05 Febit Holding Gmbh Ensembles complexes de miarn en tant que biomarqueurs non invasifs pour glioblastome
EP2474617A1 (fr) 2011-01-11 2012-07-11 InteRNA Technologies BV MIR pour traiter une nouvelle angiogenèse
CN102174516A (zh) * 2011-01-20 2011-09-07 中南大学 一种与ebv感染相关的鼻咽癌诊断和治疗的分子靶标及其应用
CN105969773A (zh) 2011-02-03 2016-09-28 米尔纳医疗股份有限公司 Mir-124的合成模拟物
CN103476931A (zh) 2011-02-03 2013-12-25 米尔纳医疗股份有限公司 Mir-34的合成模拟物
CA2828772A1 (fr) 2011-03-07 2012-09-13 The Ohio State University Activite mutatrice induite par l'inflammation des liaisons au microarn-155 (mir-155) et le cancer
US8945829B2 (en) 2011-03-22 2015-02-03 Cornell University Distinguishing benign and malignant indeterminate thyroid lesions
WO2012142199A1 (fr) * 2011-04-14 2012-10-18 The Regents Of The University Of Colorado, A Body Corporate Miarn dérégulé dans le sarcome d'ewing
US9603949B2 (en) * 2011-09-01 2017-03-28 University Of Iowa Research Foundation Oligonucleotide-based probes for detection of bacterial nucleases
US9322016B2 (en) * 2011-09-07 2016-04-26 3-D Matrix Ltd. MicroRNA-based methods and assays for osteosarcoma
WO2013040251A2 (fr) 2011-09-13 2013-03-21 Asurgen, Inc. Méthodes et compositions incluant mir-135b, permettant de faire la distinction entre un cancer du pancréas et une maladie pancréatique bénigne
CA2850223A1 (fr) 2011-10-06 2013-04-11 Eva Van Rooij Regulation de l'homeostasie energetique du corps entier par la regulation de microarn
CN104364390B (zh) 2011-10-14 2016-08-24 俄亥俄州立大学 与卵巢癌相关的方法和材料
WO2013067048A1 (fr) * 2011-10-31 2013-05-10 The Ohio State University Matériels et méthodes associés à mir-221 et à un carcinome hépatocellulaire
US9315812B2 (en) * 2011-11-03 2016-04-19 Kaohsiung Medical University Methods of using microRNA 195 in providing neuroprotection
KR101414383B1 (ko) * 2011-11-09 2014-07-10 경희대학교 산학협력단 Ｄｌｋ-1 유전자 발현억제용 조성물
CA2859430A1 (fr) 2011-12-13 2013-06-20 Ohio State Innovation Foundation Procedes et compositions se rapportant a mir-21 et mir-29a, a l'inhibition d'exosome, et a la metastase cancereuse
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
EP2804960A4 (fr) 2012-01-20 2015-08-19 Univ Ohio State Signatures de marqueurs biologiques du cancer du sein concernant le pouvoir envahissant et le pronostic
US20150190532A1 (en) 2012-04-04 2015-07-09 The Trustees Of Columbia University In The City Of New York Smooth muscle specific inhibition for anti-restenotic therapy
US8846316B2 (en) 2012-04-30 2014-09-30 Industrial Technology Research Institute Biomarker for human liver cancer
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
EP3435084B1 (fr) 2012-08-16 2023-02-22 Decipher Biosciences, Inc. Pronostic du cancer de la prostate utilisant des biomarqueurs
KR101480366B1 (ko) * 2013-01-08 2015-01-09 서울대학교산학협력단 ｍｉｃｒｏＲＮＡ를 이용한 방사선 반응 조절
CN103160509B (zh) * 2013-03-07 2015-02-18 新乡医学院第一附属医院 一种与食管癌术后早期复发和预后相关的miRNA标志物及其应用
WO2014151764A2 (fr) 2013-03-15 2014-09-25 Veracyte, Inc. Procédés et compositions pour classification d'échantillons
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
GB2514549A (en) * 2013-05-27 2014-12-03 Nat Univ Ireland A biomarker of breast cancer
CN103417987B (zh) * 2013-07-17 2015-06-24 上海交通大学医学院附属瑞金医院 miR-148用于制备控制胰岛β细胞的增殖的药物
CA2918858A1 (fr) * 2013-08-05 2015-02-12 Vib Vzw Inhibiteurs de carnitine palmitoyltransferase 1 pour inhiber l'angiogenese pathologique
EP3036345A2 (fr) * 2013-08-19 2016-06-29 Notre Dame Du Lac Procédé et composition pour la détection de hpv oncogène
WO2015095862A2 (fr) * 2013-12-20 2015-06-25 The Feinstein Institute For Medical Research Biomarqueurs de micro-arn pour le cancer de l'ovaire
US10619219B2 (en) 2014-02-07 2020-04-14 University Of Iowa Research Foundation Oligonucleotide-based probes and methods for detection of microbes
WO2015175642A2 (fr) * 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Méthodes et compositions pharmaceutiques pour la prévention ou le traitement d'une maladie
WO2015179712A1 (fr) 2014-05-22 2015-11-26 University Of Notre Dame Du Lac Capteur à membrane intégrée permettant la détection moléculaire rapide
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
CN104131113B (zh) * 2014-08-22 2016-01-06 上海赛安生物医药科技有限公司 一种miRNA检测试剂盒及其应用
WO2016046640A2 (fr) 2014-09-26 2016-03-31 Medical Prognosis Institute A/S Procédés de prédiction de la réactivité à un médicament
EP3770274A1 (fr) 2014-11-05 2021-01-27 Veracyte, Inc. Systèmes et procédés de diagnostic de la fibrose pulmonaire idiopathique sur des biopsies transbronchiques à l'aide de l'apprentissage automatique et de données de transcription dimensionnelle élevée
AU2016258171B2 (en) 2015-05-06 2021-12-09 LGC Clinical Diagnostics, Inc. Liposomal preparations for non-invasive-prenatal or cancer screening
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
US12049625B2 (en) 2016-01-14 2024-07-30 The Brigham And Women's Hospital, Inc. Genome editing for treating glioblastoma
MA45477A (fr) 2016-04-15 2019-02-20 Res Inst Nationwide Childrens Hospital Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire
CN106086178B (zh) * 2016-06-16 2020-03-31 朱伟 一种与胃癌辅助诊断相关的血清miRNA标志物及其应用
CN106282347A (zh) * 2016-08-17 2017-01-04 中南大学 HoxC11作为生物标志物在制备肺腺癌的预诊断试剂中的应用
CN110506127B (zh) 2016-08-24 2024-01-12 维拉科特Sd公司 基因组标签预测前列腺癌患者对术后放射疗法应答性的用途
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
WO2018080658A1 (fr) 2016-10-27 2018-05-03 Aalborg University Ciblage thérapeutique d'un microarn pour traiter la dystrophie musculaire de duchenne
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
WO2018132916A1 (fr) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Sous-typage moléculaire, pronostic et traitement du cancer de la vessie
EP3593140A4 (fr) 2017-03-09 2021-01-06 Decipher Biosciences, Inc. Sous-typage du cancer de la prostate pour prédire la réponse à une thérapie hormonale
EP3596112A2 (fr) 2017-03-17 2020-01-22 Newcastle University Délivrance par vecteur viral adéno-associé d'un fragment de micro-dystrophine pour traiter la dystrophie musculaire
WO2018187673A1 (fr) * 2017-04-06 2018-10-11 The University Of Vermont And State Agricultural College Expression de signature de miarn dans le cancer
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019018553A1 (fr) * 2017-07-18 2019-01-24 The Broad Institute, Inc. Procédés de production de modèles de cellules cancéreuses humaines et procédés d'utilisation
WO2019028285A2 (fr) 2017-08-04 2019-02-07 Genomedx, Inc. Utilisation d'une expression génique spécifique des cellules immunitaires pour le pronostic du cancer de la prostate et la prédiction de la sensibilité à la radiothérapie
EP3688181A4 (fr) 2017-09-29 2021-06-16 University of Iowa Research Foundation Compositions et procédés numériques de détection de nucléase
WO2019078916A1 (fr) 2017-10-18 2019-04-25 Research Institute At Nationwide Children's Hospital Administration par vecteur à virus adéno-associé de micro-dystrophine spécifique de muscles pour traiter la dystrophie musculaire
CN108103202A (zh) * 2018-03-06 2018-06-01 苏州吉玛基因股份有限公司 与肝癌诊疗相关的7种血清外泌体miRNAs及其应用
AU2019290544B2 (en) 2018-06-18 2026-01-22 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
CN109758471A (zh) * 2019-02-26 2019-05-17 贵州理工学院 一种microRNA及其靶基因在结直肠癌中的应用
EP3969619A1 (fr) * 2019-05-13 2022-03-23 Yeda Research and Development Co. Ltd Biomarqueurs de micro-adn acellulaire pour le pronostic et le diagnostic de maladies neurodégénératives
WO2021072163A1 (fr) * 2019-10-09 2021-04-15 The Regents Of The University Of California Compositions et procédés de reprogrammation des cellules non neuronales à limite d'âge
CN111471683B (zh) * 2020-04-15 2021-09-07 湖南省科域生物医药科技有限公司 miR-93-5p作为诊断和治疗胃癌标志物的应用
US20230407401A1 (en) * 2020-05-29 2023-12-21 National Institute Of Immunology Dna damage dependent microrna signature for cancers, methods and uses related thereto
CN111500739B (zh) * 2020-06-15 2022-05-17 南通大学附属医院 一种用于检测鼻咽癌预后的生物标志物及其应用
WO2022040530A2 (fr) * 2020-08-21 2022-02-24 Capsida, Inc. Compositions de virus pour traiter la mucopolysaccharidose ii
CN112941185B (zh) * 2021-03-26 2023-06-23 杭州医学院 miR-29a作为标志物在制备恶性间皮瘤检测试剂盒中的应用
CN113684277B (zh) * 2021-09-06 2022-05-17 南方医科大学南方医院 一种基于基因组拷贝数变异的生物标志物预测卵巢癌同源重组缺陷的方法及应用
CN115772526B (zh) * 2022-07-20 2025-01-24 西北农林科技大学 西瓜ClmiR159-3P及其前体基因的应用
US20240150765A1 (en) * 2022-11-08 2024-05-09 Curamir Therapeutics, Inc. Mercaptopurine-modified mirna for treating cancer
CN116426648B (zh) * 2023-03-27 2024-03-08 艾一生命科技(广东)有限公司 一种用于鉴定干细胞外泌体的miRNA组合及其qRCR引物
CN119320773B (zh) * 2024-10-17 2025-10-28 中山大学 华支睾吸虫细胞外囊泡来源的MicroRNA及其在华支睾吸虫所致胆管癌中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043387A2 (fr) * 2002-11-13 2004-05-27 Thomas Jefferson University Compositions et procedes de diagnostic et de therapie du cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
ATE120497T1 (de) 1988-05-09 1995-04-15 Univ Temple Verfahren zur voraussage der wirksamkeit einer antineoplastichen behandlung bei einzelnen patienten.
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
CA2937159C (fr) * 2001-09-28 2017-11-28 Thomas Tuschl Molecules de micro-arn
EP1537227B1 (fr) 2002-05-31 2010-02-17 The Regents Of The University Of California Procede d'interference efficace par arn dans des cellules de mammifere
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP1648914A4 (fr) * 2003-07-31 2009-12-16 Regulus Therapeutics Inc Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
CA2554818A1 (fr) 2004-02-09 2005-08-25 Thomas Jefferson University Diagnostic et traitement de cancers a l'aide de microarn present dans ou au voisinage de caracteristiques chromosomiennes liees aux cancers
CN101341259B (zh) * 2005-08-01 2011-12-21 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
JP5451077B2 (ja) * 2006-01-05 2014-03-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 肺癌の診断、予後診断及び治療のためのマイクロｒｎａを基盤とした方法及び組成物
EP2505668A3 (fr) * 2006-01-05 2013-01-09 The Ohio State University Research Foundation Procédés à base de micro ARN pour le diagnostic d'un cancer du colon, du poumon, et du pancreas
AU2007205257B2 (en) * 2006-01-05 2013-07-25 The Ohio State University Research Foundation MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
WO2009108856A2 (fr) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation Signatures de microarn associées à la leucémie lymphoïde chronique humaine (llc) et leurs utilisations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043387A2 (fr) * 2002-11-13 2004-05-27 Thomas Jefferson University Compositions et procedes de diagnostic et de therapie du cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BARTEL DAVID P: "MicroRNAs: genomics, biogenesis, mechanism, and function.", CELL. 23 JAN 2004, vol. 116, no. 2, 23 January 2004 (2004-01-23), pages 281 - 297, XP002358495, ISSN: 0092-8674 *
CALIN G A ET AL: "Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 99, no. 24, 26 November 2002 (2002-11-26), pages 15524 - 15529, XP002982123, ISSN: 0027-8424 *
CALIN G A ET AL: "MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 101, no. 32, 10 August 2004 (2004-08-10), pages 11755 - 11760, XP002339402, ISSN: 0027-8424 *
CALIN GEORGE ADRIAN ET AL: "A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.", THE NEW ENGLAND JOURNAL OF MEDICINE. 27 OCT 2005, vol. 353, no. 17, 27 October 2005 (2005-10-27), pages 1793 - 1801, XP009058593, ISSN: 1533-4406 *
CALIN GEORGE ADRIAN ET AL: "Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2 MAR 2004, vol. 101, no. 9, 2 March 2004 (2004-03-02), pages 2999 - 3004, XP002358496, ISSN: 0027-8424 *
MCMANUS MICHAEL T: "MicroRNAs and cancer.", SEMINARS IN CANCER BIOLOGY. AUG 2003, vol. 13, no. 4, August 2003 (2003-08-01), pages 253 - 258, XP002358494, ISSN: 1044-579X *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946177B2 (en) 2004-11-12 2015-02-03 Mima Therapeutics, Inc Methods and compositions involving miRNA and miRNA inhibitor molecules
US8658370B2 (en) 2005-08-01 2014-02-25 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
US8481505B2 (en) 2005-09-12 2013-07-09 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
US8377637B2 (en) 2006-01-05 2013-02-19 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-17-3P
US7943318B2 (en) 2006-01-05 2011-05-17 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
US8361710B2 (en) 2006-01-05 2013-01-29 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer using miR-21
US8389210B2 (en) 2006-01-05 2013-03-05 The Ohio State University Research Foundation MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
US7985584B2 (en) 2006-03-20 2011-07-26 The Ohio State University Research Foundation MicroRNA fingerprints during human megakaryocytopoiesis
US8354224B2 (en) 2006-03-20 2013-01-15 The Ohio State University MicroRNA fingerprints during human megakaryocytopoiesis
US8084199B2 (en) 2006-07-13 2011-12-27 The Ohio State University Research Foundation Method of diagnosing poor survival prognosis colon cancer using microRNA-21
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
US8034560B2 (en) 2007-01-31 2011-10-11 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML)
US8465917B2 (en) 2007-06-08 2013-06-18 The Ohio State University Research Foundation Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells
US8361722B2 (en) 2007-06-15 2013-01-29 The Ohio State University Research Foundation Method for diagnosing acute lymphomic leukemia (ALL) using miR-221
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
US8367632B2 (en) 2007-07-31 2013-02-05 Ohio State University Research Foundation Methods for reverting methylation by targeting methyltransferases
US8465918B2 (en) 2007-08-03 2013-06-18 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
US8466119B2 (en) 2007-08-22 2013-06-18 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of EPHA7 and ERK phosphorylation in human acute leukemias
US8911998B2 (en) 2007-10-26 2014-12-16 The Ohio State University Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof
US9125923B2 (en) 2008-06-11 2015-09-08 The Ohio State University Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy
US9803202B2 (en) 2012-06-21 2017-10-31 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
US10337005B2 (en) 2012-06-21 2019-07-02 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
US10280422B2 (en) 2015-01-20 2019-05-07 MiRagen Therapeutics, Inc. MiR-92 inhibitors and uses thereof
US9771585B2 (en) 2015-06-05 2017-09-26 MiRagen Therapeutics, Inc. miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)
US9994852B2 (en) 2015-06-05 2018-06-12 MiRagen Therapeutics, Inc. Oligonucleotide compositions and uses thereof
US10316318B2 (en) 2015-06-05 2019-06-11 MiRagen Therapeutics, Inc. Oligonucleotide compositions and uses thereof

Also Published As

Publication number Publication date
US9150859B2 (en) 2015-10-06
US20140256040A1 (en) 2014-09-11
US20130330403A1 (en) 2013-12-12
CA2554818A1 (fr) 2005-08-25
US20100234241A1 (en) 2010-09-16
US9506065B2 (en) 2016-11-29
EP2295604A3 (fr) 2012-05-09
WO2005078139A2 (fr) 2005-08-25
EP1713938A2 (fr) 2006-10-25
US20150368647A1 (en) 2015-12-24
US20060105360A1 (en) 2006-05-18
US20170175123A1 (en) 2017-06-22
US8778676B2 (en) 2014-07-15
US20100203544A1 (en) 2010-08-12
US7723030B2 (en) 2010-05-25
EP2295604A2 (fr) 2011-03-16
EP2295604B1 (fr) 2015-04-08

Similar Documents

Publication Publication Date Title
WO2005078139A3 (fr) Diagnostic et traitement de cancers a l'aide de microarn present dans ou au voisinage de caracteristiques chromosomiennes liees aux cancers
WO2008063769A3 (fr) Altérations de l'expression du gène erg spécifiques au cancer de la prostate, et procédés de détection et de traitement en fonction de ces altérations
WO2007112330A3 (fr) Compositions et méthodes pour détecter, pronostiquer et traiter un cancer du côlon
WO2009108866A3 (fr) Signatures en micro-arn associées à la cytogénétique et au pronostic dans la leucémie myéloïde aiguë (aml) et leurs utilisations
WO2012018613A3 (fr) Modification de l'issue des cancers suivant la constitution génétique
Pérez-Ramírez et al. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer
WO2006138275A3 (fr) Compositions et procedes de traitement et de diagnostic de cancer
WO2008117314A3 (fr) Variants génétiques du chr2 et chr16 utilisés comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
WO2006110264A3 (fr) Procedes et compositions permettant de predire le deces du au cancer et la survie au cancer de la prostate a l'aide de signatures d'expression genique
WO2007033187A3 (fr) Fusion geniques recurrentes dans le cancer de la prostate
WO2008073878A3 (fr) Profil d'expression de gène de carcinomes œsophagiens
WO2004016758A3 (fr) Motifs d'expression de cellules endotheliales cerebrales
WO2009059317A3 (fr) Prédiction d'amd avec snps à l'intérieur ou près de c2, facteur b, plekha1, htra1, prelp ou loc387715
WO2007134210A3 (fr) Méthodes et compositions destinées au diagnostic et au traitement du cancer
WO2005113816A3 (fr) Methodes de diagnostic ou de traitement du cancer de la prostate au moyen du gene erg, seul ou combine a d'autres genes surexprimes ou sous-exprimes dans le cancer de la prostate
WO2003056036A3 (fr) Genes
WO2006135886A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer
WO2008054828A3 (fr) Signature de l'expression de microarn pour la prédiction de la survie et des métastases dans le carcinome hépato-cellulaire
WO2009131887A3 (fr) Procédés d’utilisation de mir-210 comme biomarqueur de l’hypoxie et comme agent thérapeutique dans le traitement du cancer
WO2005116259A3 (fr) Utilisation du profilage de l'expression genetique pour prevoir les chances de survie d'un patient atteint d'un cancer
IL184478A0 (en) Compositions, methods and kits for the diagnosis carriers of mutation in the brca1 and brca2 genes and early diagnosis of cancerous disorders associated with mutations in brca1 and brca2 gens
WO2005000087A3 (fr) Produits genetiques exprimes de facon differentielle dans des cellules cancereuses du colon et leurs methodes d'utilisation ii
WO2008089465A3 (fr) Polymorphismes géniques comme prédicteurs spécifiques au sexe dans la thérapie contre le cancer
WO2006037462A3 (fr) Marqueurs du cancer
Croce Introduction to the role of microRNAs in cancer diagnosis, prognosis, and treatment

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11194055

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 11194055

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2554818

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005723130

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005723130

Country of ref document: EP